Why the study?
The choice between direct oral anticoagulants and warfarin in patients with stable coronary artery disease and atrial fibrillation remains controversial.
Do Direct Oral Anticoagulants (DOACs) reduce stroke/systemic embolism and bleeding compared to warfarin in patients with stable coronary artery disease and atrial fibrillation?
Population
6524 patients with SCAD and AF across 5 RCTs
Comparison
DOACs vs warfarin
Design
Systematic review and network meta-analysis of RCTs
Authors
Loading...
DOACs reduce stroke/SE and intracranial bleeding vs warfarin in SCAD+AF; reinforces guideline preference and extends dosing comparisons.
Do Direct Oral Anticoagulants (DOACs) reduce stroke/systemic embolism and bleeding compared to warfarin in patients with stable coronary artery disease and atrial fibrillation?
In patients with stable coronary artery disease and atrial fibrillation, DOACs are more effective and safer than warfarin, significantly reducing the risk of stroke/systemic embolism and intracranial bleeding.
Ma et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: